American Research & Management Company’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $767K | Sell |
10,790
-2,735
| -20% | -$198K | 0.21% | 74 |
|
|
2022
Q2 | $1.04M | Sell |
13,525
-3,625
| -21% | -$276K | 0.27% | 66 |
|
|
2022
Q1 | $1.25M | Sell |
17,150
-200
| -1% | -$13.4K | 0.28% | 65 |
|
|
2021
Q4 | $1.08M | Sell |
17,350
-370
| -2% | -$21.7K | 0.23% | 68 |
|
|
2021
Q3 | $1.05M | Sell |
17,720
-1,275
| -7% | -$84K | 0.24% | 67 |
|
|
2021
Q2 | $1.27M | Sell |
18,995
-4,970
| -21% | -$324K | 0.29% | 63 |
|
|
2021
Q1 | $1.51M | Sell |
23,965
-1,167
| -5% | -$72.6K | 0.36% | 61 |
|
|
2020
Q4 | $1.56M | Buy |
25,132
+150
| +0.6% | +$9.22K | 0.41% | 56 |
|
|
2020
Q3 | $1.51M | Sell |
24,982
-865
| -3% | -$52.1K | 0.44% | 55 |
|
|
2020
Q2 | $1.52M | Sell |
25,847
-80
| -0.3% | -$4.79K | 0.46% | 55 |
|
|
2020
Q1 | $1.45M | Sell |
25,927
-4,240
| -14% | -$259K | 0.55% | 52 |
|
|
2019
Q4 | $1.94M | Buy |
30,167
+15,615
| +107% | +$894K | 0.57% | 49 |
|
|
2019
Q3 | $738K | Hold |
14,552
| – | – | 0.22% | 83 |
|
|
2019
Q2 | $660K | Sell |
14,552
-100
| -0.7% | -$4.66K | 0.2% | 89 |
|
|
2019
Q1 | $699K | Hold |
14,652
| – | – | 0.2% | 90 |
|
|
2018
Q4 | $762K | Hold |
14,652
| – | – | 0.26% | 79 |
|
|
2018
Q3 | $910K | Hold |
14,652
| – | – | 0.27% | 74 |
|
|
2018
Q2 | $811K | Buy |
14,652
+13,360
| +1,034% | +$722K | 0.28% | 71 |
|
|
2018
Q1 | $82K | Hold |
1,292
| – | – | 0.03% | 155 |
|
|
2017
Q4 | $79K | Buy |
1,292
+250
| +24% | +$15.6K | 0.02% | 159 |
|
|
2017
Q3 | $66K | Hold |
1,042
| – | – | 0.02% | 158 |
|
|
2017
Q2 | $58K | Hold |
1,042
| – | – | 0.02% | 160 |
|
|
2017
Q1 | $57K | Sell |
1,042
-1,048
| -50% | -$57.5K | 0.02% | 154 |
|
|
2016
Q4 | $122K | Sell |
2,090
-456
| -18% | -$24.9K | 0.04% | 130 |
|
|
2016
Q3 | $137K | Buy |
2,546
+264
| +12% | +$17K | 0.05% | 124 |
|
|
2016
Q2 | $168K | Sell |
2,282
-725
| -24% | -$51.2K | 0.06% | 109 |
|
|
2016
Q1 | $192K | Buy |
3,007
+4
| +0.1% | +$252 | 0.08% | 106 |
|
|
2015
Q4 | $207K | Sell |
3,003
-903
| -23% | -$59.7K | 0.09% | 105 |
|
|
2015
Q3 | $231K | Buy |
3,906
+6
| +0.2% | +$381 | 0.1% | 102 |
|
|
2015
Q2 | $259K | Buy |
3,900
+6
| +0.2% | +$395 | 0.11% | 101 |
|
|
2015
Q1 | $251K | Sell |
3,894
-65
| -2% | -$4.07K | 0.1% | 100 |
|
|
2014
Q4 | $234K | Buy |
3,959
+6
| +0.2% | +$338 | 0.09% | 102 |
|
|
2014
Q3 | $202K | Buy |
3,953
+7
| +0.2% | +$350 | 0.07% | 109 |
|
|
2014
Q2 | $191K | Buy |
3,946
+107
| +3% | +$5.27K | 0.07% | 114 |
|
|
2014
Q1 | $199K | Sell |
3,839
-92
| -2% | -$4.89K | 0.07% | 115 |
|
|
2013
Q4 | $209K | Buy |
3,931
+7
| +0.2% | +$357 | 0.07% | 111 |
|
|
2013
Q3 | $182K | Buy |
3,924
+8
| +0.2% | +$351 | 0.07% | 112 |
|
|
2013
Q2 | $175K | Buy |
+3,916
| New | +$170K | 0.07% | 113 |
|
Other funds holding BMY
American Research & Management Company's BMY Position: Q3 2022 in Review
American Research & Management Company reduced its Bristol-Myers Squibb (BMY) stake by 20% in Q3 2022, selling an estimated $198K and leaving 10,790 shares worth $767K. The position accounts for 0.21% of the portfolio, ranked #74.
American Research & Management Company first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.94M in Q4 2019. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- American Research & Management Company held 10,790 shares of Bristol-Myers Squibb worth $767K as of Q3 2022.
- American Research & Management Company sold 2,735 Bristol-Myers Squibb shares in Q3 2022, an estimated $198K.
- Bristol-Myers Squibb made up 0.21% of American Research & Management Company's portfolio in Q3 2022, its #74 holding.
- American Research & Management Company first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Bristol-Myers Squibb position peaked at $1.94M in Q4 2019.
- 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.